Quick answer
A medical device sales pipeline has to be built for a long, committee-driven cycle, not a quarterly SaaS motion. Medical device deals commonly run 12 to 24 months and involve 8 to 15 stakeholders across clinical, biomed, procurement and finance, so your stages should map to the hospital's actual buying gates: clinical champion, evidence review, evaluation, biomed and safety sign-off, value-analysis committee, and procurement or GPO contracting. Build the stages around those gates, track every stakeholder per account, and forecast on the cycle you really have rather than the one you wish you had.
Why a medical device pipeline is different
Most pipeline advice assumes a short cycle, one or two decision makers, and a budget that is already approved. Medical devices break all three assumptions.
A device sells into a hospital or health system that buys slowly, demands clinical evidence before anyone commits, and routes the decision through a value-analysis committee (VAC). As the medical devices industry page lays out, a device can be clearly better than what the hospital uses today and still take a year or more to land. That is not a sign the deal is dead. It is the cycle working as designed.
So the first job is to stop measuring these deals like fast ones. A generic pipeline with "demo booked" and "proposal sent" tells you almost nothing about a deal whose real progress is "cleared biomed review" or "accepted onto the VAC agenda for next quarter." The pipeline has to speak the buyer's language.
What stages should a medical device pipeline have?
Build stages around the gates a device has to clear inside the hospital. Each stage should represent a real change in commitment, with an exit criterion tied to the person or committee who has to say yes.
| Stage | What it means | Exit criterion |
|---|---|---|
| Identified account | Target hospital or system matches your ICP | Clinical and economic fit confirmed |
| Champion engaged | A clinician or department head sees the value | Champion agrees to sponsor internally |
| Evidence shared | Clinical and economic proof delivered | Champion accepts the evidence is sufficient |
| Evaluation or trial | Hands-on use, in-service, or a limited trial | Evaluation complete with a documented result |
| Biomed and safety review | Clinical engineering checks safety and integration | Biomed sign-off obtained |
| VAC submission | Value-analysis committee reviews evidence and cost | Committee approves, or requests more data |
| Procurement and GPO | Pricing, contract and GPO terms negotiated | Contract terms agreed |
| Purchase order | Budget approved and PO issued | PO received |
Treat this as a template to adapt to how you actually sell, not a rule. The general principles behind good stages are covered in how to build a sales pipeline and sales pipeline stages. The medical device version just adds the committee and procurement gates that a hospital genuinely runs.
Why the VAC stage is the one most teams miss
The value-analysis committee is where device deals live or die, and where founder-led pipelines tend to lose visibility. The VAC meets on its own schedule, asks for evidence, and weighs clinical benefit against cost for the whole system. A deal can sit "in committee" for a quarter and still be healthy. If your pipeline collapses that into a single "negotiation" stage, you cannot tell a deal that is progressing from one that has quietly stalled.
Give the committee its own stage, record when it meets, and track exactly what it asked for. That is how a long deal stays legible.
How do you map the committee into the pipeline?
Because a device decision runs through 8 to 15 people, the opportunity is really a set of relationships, not a single contact. Map each buyer role to the account and track them separately. Drawing on the roles the medical devices page sets out:
- Clinician or department head. Your champion, who judges clinical value and sponsors the device internally.
- Biomed or clinical engineering. The gatekeeper on safety and integration. Nothing moves to purchase without their sign-off.
- Value-analysis committee. Approves on evidence and cost, on its own cadence.
- Procurement and GPO. Negotiate pricing and contracts, often within existing group purchasing agreements.
- Executive or finance sponsor. Approves the budget.
Gartner has found the typical B2B buying group involves six to ten decision makers. Medical devices sit at the high end of that and often past it, which is exactly why a lone "contact" never represents a real opportunity. Build your pipeline around accounts and the committee inside them. For how to structure this in your system, see CRM setup for medical device companies.
How should you forecast a 12 to 24 month cycle?
Honestly, and with the cycle length built in. Two things matter more than a precise model.
First, weight by stage against the real gates. A deal that has cleared biomed and is on the VAC agenda is far more likely to close than one with an enthusiastic clinician and no evidence accepted yet. Your stage weighting should reflect how hospitals actually commit, not an even gradient.
Second, forecast on time, not just probability. A device deal that is genuinely progressing may still be nine months from a PO. If your forecast assumes a one-quarter close, every healthy long deal looks like a miss. Record an expected decision window per stage and let the forecast span quarters.
Keep the model simple while volume is low. With a handful of live deals, a stage-weighted view plus an honest per-account read beats a complicated model built on too little data. The point is to see where each deal sits against the hospital's gates and whether you have enough at-bats in motion to hit the number.
What should you track per deal?
For a long, multi-stakeholder cycle, the useful signals are concrete:
- Stakeholders engaged per account, against the full committee. A deal with only a clinician is earlier than it looks.
- Evidence status: what the champion and the VAC have accepted, and what is still outstanding.
- Gate dates: when biomed reviewed, when the VAC meets next, when the contract is up.
- Days in stage, so a deal that has genuinely stalled is distinguishable from one that is simply working through a slow gate.
- GPO and contract context, so procurement does not surprise you at the end.
Track these at the account and opportunity level, never on a lone lead. The deals that close next year are the relationships and evidence you put in front of the right committees now, so the pipeline's job is to keep all of that visible for months without anything falling through.
Where Enablemnt fits
Everything above is the work: stages that match the hospital's gates, the full committee mapped per account, and a forecast that respects a multi-quarter cycle. The reason it rarely gets built well at an early device company is that it takes weeks to stand up, and a founder closing the first deals does not have those weeks.
Enablemnt is your embedded RevOps and outbound team. We build the pipeline this article describes in a fixed 14-day sprint: evidence-led targeting, committee mapping per account, and a CRM with stages and hygiene rules built for long, regulated device cycles. You own all of it at the end, documented, and can run it in-house or keep us on to operate it.
If you want a device pipeline built right the first time rather than assembled over a year of selling, tell us about your company and we will map your GTM blueprint on a short call.
Follow Enablemnt AI on LinkedInShort, practical posts on GTM, outbound and RevOps for early-stage B2B founders.FollowFrequently asked questions
- How long is a medical device sales cycle?
- Medical device cycles commonly run 12 to 24 months, because a device has to clear clinical evaluation, biomed and safety sign-off, a value-analysis committee, and procurement or GPO contracting before a purchase order is issued. Your pipeline stages and forecast should assume a multi-quarter cycle from the start, and track each stakeholder group separately so a deal that looks stalled is really just working through the next gate.
- What pipeline stages should a medical device company use?
- Stages that map to the hospital's buying gates, not a generic template: identified account, clinical champion engaged, evidence shared, evaluation or trial, biomed and safety review, value-analysis committee submission, procurement and GPO contracting, and purchase order. Each stage should have a clear exit criterion tied to the committee or buyer who has to say yes before the deal advances.
- How many stakeholders are in a medical device deal?
- Typically 8 to 15 across clinical, biomed or clinical engineering, procurement, and finance. The clinician champions the device on clinical value, biomed gates it on safety and integration, the value-analysis committee approves on evidence and cost, procurement and the GPO negotiate the contract, and an executive or finance sponsor signs off the budget. A single contact is never the whole opportunity.
Keep reading
- CRM setup for medical device companiesHow to set up a CRM for a medical device company: modeling accounts and committees, stages for long cycles, evidence tracking, and the fields that matter.
- Go-to-market (GTM) strategy for medical device startupsA go-to-market strategy for medical device startups: evidence-led targeting, committee mapping, hospital procurement and GPOs, and the infrastructure to run it.
- How to build a sales pipeline (step by step)A step-by-step guide to building a sales pipeline for early-stage B2B startups: define stages, set entry and exit criteria, and keep it clean enough to trust.
- Sales pipeline stages for B2B, explainedWhat the stages of a B2B sales pipeline mean, with an example stage set, clear exit criteria, and how to adapt them to how your startup actually sells.
Filed under By industry. Written by Enablemnt AI.